Creo Medical Group PLC Change of accounting reference date (6846L)
April 20 2018 - 10:38AM
UK Regulatory
TIDMCREO
RNS Number : 6846L
Creo Medical Group PLC
20 April 2018
Creo Medical Group plc
Change of accounting reference date
Chepstow, Wales - 20 April 2018 - Creo Medical Group plc (AIM:
CREO) ("Creo" or the "Company"), a medical device company focused
on the emerging field of surgical endoscopy, announces that it has
changed its accounting reference date from 30 June to 31 December
with immediate effect.
As a result of the change of accounting reference date, the
Company's reporting calendar will be as follows:
-- Unaudited interims for the 6 month period ending 30 June 2018
to be published by 30 September 2018; and
-- Audited results for the 18 month period to 31 December 2018
to be published by 30 April 2019.
Thereafter, interim and annual reports will be published each
year for the 6 months to 30 June and 12 months to 31 December
respectively, in accordance with the AIM Rules for Companies.
Contacts
Creo Medical: Cenkos: FTI Consulting:
Richard Rees Camilla Hume/Mark Connelly (NOMAD) Brett Pollard / Mo Noonan
+44 (0)129 160 6005 Michael Johnson / Russell Kerr (Sales) +44 (0)203 727 1000
+44 (0)207 397 8900 creo@fticonsulting.com
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and radiowave energy to surgical endoscopy. Creo
has developed CROMA, an electrosurgical platform that combines
bipolar radiofrequency for precise localised cutting and microwave
for controlled coagulation. This technology provides physicians
with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA platform to market
through a suite of medical devices which the Company has designed,
initially for the emerging field of GI therapeutic endoscopy, an
area with high unmet needs. The CROMA platform will be developed
further for bronchoscopy and laparoscopy procedures. The Company
believes its technology can impact the landscape of surgery and
endoscopy by providing safer, less-invasive and more cost-efficient
option of treatment.
For more information about Creo Medical please see our website,
www.creomedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSEMFISFASEDL
(END) Dow Jones Newswires
April 20, 2018 11:38 ET (15:38 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024